US biotech Moderna (Nasdaq: MRNA) continues to add to the optimism over mRNA-4157 (V940), its investigational cancer vaccine being developed alongside Merck & Co (NYSE: MRK).
The mRNA specialist has announced the first presentation of detailed results from the Phase IIb KEYNOTE-942/mRNA-4157-P201 trial evaluating the vaccine alongside Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV).
In the overall intention-to-treat population, adjuvant treatment with mRNA-4157 (V940) in combination with Keytruda demonstrated a statistically-significant and clinically-meaningful improvement in recurrence-free survival (RFS), and reduced the risk of recurrence or death by 44% compared with Keytruda alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze